Format

Send to

Choose Destination
Cell Metab. 2017 Oct 3;26(4):595-597. doi: 10.1016/j.cmet.2017.09.016.

Antigen-Specific Peptide Immunotherapy for Type 1 Diabetes: Proof of Safety, Hope for Efficacy.

Author information

1
Global Research Project Management, Novo Nordisk A/S, Måløv, Denmark.
2
Type 1 Diabetes Research Center, Novo Nordisk, Seattle, WA, USA; Type 1 Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92014, USA. Electronic address: matthias@lji.org.

Abstract

Antigen-specific immunotherapy has long been hailed as the ideal disease-modifying approach for type 1 diabetes, both for disease prevention and reversal. A small phase 1 trial now demonstrates safety of a peptide-based treatment in recently diagnosed adults.

PMID:
28978425
DOI:
10.1016/j.cmet.2017.09.016
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center